Hermann A. M. Mucke (born 4 September 1955) is an Austrian bioscientist with a peer-review publishing record in the fields of molecular biology, neuropsychiatry, cardiology and ophthalmology, mostly from the perspective of drug development. He is also a management consultant and entrepreneur working and publishing in biopharmaceutical strategic knowledge management, intellectual property management, and life science technology assessment.
Academic career
Hermann Mucke attended the University of Vienna where he obtained his master and Ph.D. degrees in biochemistry. This earliest plant molecular biology phase of Mucke's work concerned the characterization and partial sequencing of the Cyanophora cyanelle genome,Mucke H, Löffelhardt W, Bohnert HJ. Cyanelle Genome Organization. In: Advances in Photosynthesis Research, Vol. IV, pp. 579-582. Ed.: Chr. Sybesma, Lancaster 1984. believed to resemble early stages of chloroplast evolution according to the endosymbiotic theory.
Industry research executive
After leaving the university Mucke became executive director of research and development at an Austrian pharmaceutical company. He developed an indirect immunofluorescence assay for the detection of antibodies to the human immunodeficiency virus in human body fluids which was approved under the name Fluorognost(TM) HIV-1 by the U.S. FDA approval on 5 February 1992.List of FDA-approved HIV and hepatitis tests A human T-lymphotropic virus antibody test, developed by Mucke's team but never marketed, served to demonstrate the first evidence of retrovirus-like serological reactivity in patients with the myelodysplastic syndrome, a finding that meanwhile has been corroborated on the genomic level.
In 1994 Mucke developed a new research focus in neuropsychiatry, initially with a focus on Alzheimer's disease and related neurodegenerative diseases. He directed an R&D program for galantamine derivatives.WO/1997/026887 Use of galanthamine in the preparation of novel drugs. Published July 31, 1997 Link to PCT documentWO/2000/032199. Use of galantamine and galantamine derivatives in the case of acute functional brain damage. Published June 8, 2000 Link to PCT document Soon thereafter he began to cooperate with various pharmaceutical intelligence providers and publishers in the United States and the United Kingdom, both as an author and as a contributing editor.
Industry advisor and publisher
In 2000, Mucke resigned his executive function in the pharmaceutical industry to set up his own consulting enterprise.Pridun C; Menschen in Bewegung. wirtschaftsblatt online archive article , April 14, 2000. Accessed: 2009-06-15. Archived Since then, he has been an independent scientific advisor to life science companies and a prolific author of market and technology reports. He continues to publish his own original scientific research and commissioned reviews both in commercial and open access peer-review journals. His most recent papers demonstrate a systematic utilization of patent documents as a source of information in science, technology, and market research in the fields of ophthalmology,Mucke HAM, Mucke P, Mucke E. (2009) "International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics. Clin Ophthalmology 3: 103–109 PDF Archived renal and cardiorespiratory medicine, especially pulmonary hypertension, and endothelin receptor antagonists.
By 2009 Hermann Mucke had authored or co-authored about 50 peer reviewed original research papers and invited reviews, in addition to dozens of drug evaluations. He is also a coinventor on several patent families which concern themselves with the pharmacotherapy of alcohol abuse,WO/2002/102388 Active ingredient combination of e.g. galantamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism. Published December 27, 2002. Link to PCT documentWO/2004/014393. Medicament and method for reducing alcohol and/or tobacco consumption. Published Feb. 19, 2004. Link to PCT document nicotine dependence,WO/2003/007966. Active substance combination for medicamentous therapy of nicotine dependency. Published January 30, 2003. Link to PCT document and depression.WO/2003/053445. Use of desoxypeganine for treating clinical depression. Published July 3, 2002. Link to PCT document
Hermann Mucke is Patent Editor at the Thomson Reuters journal, Current Opinion in Investigational Drugs COID journal website and an advisor to the Antiviral Spot of Excellence Vienna (ASPEX). He is frequently interviewed by media covering the pharmaceutical industry, mostly on issues concerning the streamlining of drug development through optimization of clinical trials,Borman S: Improving Efficiency. Chemical & Engineering News Special Issue published June 19, 2006. Vol 84(25):56-78 Link to article ArchivedDavies K.: Putting the IT in Clinical Trials. BioIT World Vol. 5 Issue 3, p14. April 14, 2006. Link to article Archived new approaches to the clinical trial process,May M: Exploratory INDs: A Trial Before the Trials. BioIT World Dec. 17, 2007. Link to article Archived or medical imaging.Ward J: From Mice to Men: Is Imaging the Magic Pill for Faster Drug Development? ADVANCE for Imaging & Radiation Oncology. February 23, 2005. Link to article Archived
References
External links Peer-reviewed papers by Hermann A.M. Mucke in PubMed Dynamic query Papers by Hermann A. M. Mucke in Google Scholar Dynamic query Literature-based profile for Hermann A.M. Mucke at BiomedExperts Dynamic query